Table 4.

Univariate and multivariate analysis of factors associated with risk of incident HGAIN.^a

Covariates	Univariate				Multivariate, baseline HPV				Multivariate, persistent HPV

	HR	Lower CI	Upper CI	P	HR	Lower CI	Upper CI	P	HR	Lower CI	Upper CI	P
*All MSM*
Baseline HIV-positive vs. HIV- negative status	4.45	1.73	11.45	0.002	3.26	1.31	8.14	0.011	2.62	1.04	6.61	0.042
LGAIN at baseline	2.9	1.3	6.47	0.009	1.75	0.76	4.04	0.189	1.83	0.77	4.33	0.172
Baseline HPV infection				0.003				0.055
No high-risk HPV infection	1				1
HPV 16 and/or 18 infection	4.81	1.92	12.04	0.001	3.12	1.19	8.21	0.021
High-risk HPV infection other than HPV 16 and/or 18	1.99	0.70	5.69	0.198	1.43	0.50	4.08	0.51
HPV persistence grouping				<0.001								<0.001
No persistent high-risk HPV infection	1								1
Persistent HPV 16 and/or 18 infection	8.02	3.18	20.22	<0.001					5.16	1.89	14.08	0.001
Persistent high-risk HPV infection other than HPV 16 and/or 18	3.83	1.47	9.97	0.006					2.52	0.85	7.44	0.10
Nadir CD4 count, cells/mm³ ^b				0.004
HIV-negative	1
>350	3.51	1.13	10.9	0.03
>200-350	3.64	1.13	11.73	0.03
≤200	7.38	2.53	21.54	<0.001
Baseline CD4 count, cells/mm³ ^b				0.005
HIV-negative	1
>350	3.81	1.31	11.1	0.014
>200-350	4.12	1.3	13.04	0.016
≤200	7.46	2.47	22.52	<0.001
Baseline plasma HIV RNA, log₁₀ copies/mL ^b				0.016
HIV-negative	1
<4	5.59	1.82	17.12	0.003
4-4.99	4.05	1.42	11.58	0.009
≥5	4	1.08	14.84	0.04

HR, hazard ratio; CI, confidence interval; HPV, human papillomavirus; LGAIN, low-grade anal intraepithelial neoplasia.

For categorical covariates, the P on the line with the categorical variable name is the P for heterogeneity. P values for individual categories represent the Wald P value for the category against the reference group.

Nadir CD4 count, baseline CD4 count, and baseline plasma HIV RNA were not included in multivariate analyses for “All MSM”.